Hemab Therapeutics (NASDAQ:COAG) Reaches New 1-Year High – Here’s What Happened

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) hit a new 52-week high during trading on Monday . The company traded as high as $37.70 and last traded at $37.13, with a volume of 70017 shares traded. The stock had previously closed at $32.37.

Analysts Set New Price Targets

Several brokerages have recently issued reports on COAG. Jefferies Financial Group initiated coverage on shares of Hemab Therapeutics in a report on Tuesday, May 26th. They set a “buy” rating and a $39.00 price target for the company. Evercore initiated coverage on shares of Hemab Therapeutics in a research note on Tuesday, May 26th. They issued an “outperform” rating and a $50.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price target on shares of Hemab Therapeutics in a research note on Friday. The Goldman Sachs Group started coverage on Hemab Therapeutics in a report on Tuesday, May 26th. They issued a “buy” rating and a $36.00 target price for the company. Finally, Wedbush started coverage on shares of Hemab Therapeutics in a research report on Tuesday, May 26th. They set an “outperform” rating and a $42.00 price objective for the company. Five research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $41.40.

Hemab Therapeutics Trading Up 16.1%

Hemab Therapeutics (NASDAQ:COAG) last announced its earnings results on Thursday, May 21st. The company reported ($23.98) earnings per share for the quarter.

Insider Activity

In other Hemab Therapeutics news, major shareholder Ra Capital Management, L.P. bought 61,523 shares of the stock in a transaction on Tuesday, June 16th. The shares were purchased at an average cost of $24.98 per share, with a total value of $1,536,844.54. Following the completion of the transaction, the insider directly owned 6,444,637 shares of the company’s stock, valued at $160,987,032.26. This represents a 0.96% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Over the last three months, insiders have acquired 2,970,541 shares of company stock valued at $55,459,603.

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.